

Financial news for CNCE dated on 2020-05-04: 98 Biggest Movers From Friday

Financial news for CNCE dated on 2020-04-30: The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

Financial news for CNCE dated on 2020-04-30: Concert Pharmaceuticals Q1 EPS \$(0.700) Beats \$(0.780) Estimate

Financial news for CNCE dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for CNCE dated on 2020-04-01: Concert Pharmaceuticals Announces Plans For CTP-543 Phase 3 Trials In Alopecia Areata

Financial news for CNCE dated on 2020-03-02: 140 Biggest Movers From Friday

Financial news for CNCE dated on 2020-02-27: Concert Pharmaceuticals Q4 EPS \$(0.86) Misses \$(0.79) Estimate, Sales \$13K Beat \$10K Estimate

Financial news for CNCE dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for CNCE dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for CNCE dated on 2020-02-04: Concert Pharma Shares Rebound From Session Low Following Form 4 Filing From Co. Director Thomas Auchincloss Shows Purchase Of 1K Shares Of Co. Stock At Average Of \$10.91/Share

Financial news for CNCE dated on 2020-01-29: 70 Biggest Movers From Yesterday

Financial news for CNCE dated on 2020-01-28: 46 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CNCE dated on 2020-01-28: Concert Pharmaceuticals Prices ~4.75M Share Common Stock Offering At \$9.92/Share

Financial news for CNCE dated on 2020-01-28: The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics

Financial news for CNCE dated on 2020-01-27: Concert Pharma Reports Offering, No Size Disclosed

Financial news for CNCE dated on 2020-01-27: Concert Pharma Reports Federal Circuit Granted Motion To Vacate, Remand PTAB Decision Involving CTP-543

Financial news for CNCE dated on 2020-01-27: 70 Biggest Movers From Friday

Financial news for CNCE dated on 2020-01-23: 36 Stocks Moving in Thursday's Pre-Market Session

Financial news for CNCE dated on 2020-01-23: 70 Biggest Movers From Yesterday

Financial news for CNCE dated on 2020-01-22: 26 Biotechnology Stocks Moving In Wednesday's After-Market Session

Financial news for CNCE dated on 2020-01-22: 36 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for CNCE dated on 2020-01-22: Concert Pharmaceuticals Announces It Received A Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata

Financial news for CNCE dated on 2019-12-19: Concert Pharma Reports Successful Completion Of Open Label Trial Of CTP-543 In Patients With Alopecia Areata

Financial news for CNCE dated on 2019-12-02: Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia

Financial news for CNCE dated on 2019-11-13: 74 Biggest Movers From Yesterday

Financial news for CNCE dated on 2019-11-12: 50 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CNCE dated on 2019-11-07: Concert Pharmaceuticals Q3 EPS \$(0.72) Beats \$(0.83) Estimate, Sales \$10K May Not Compare To \$60K Estimate

Financial news for CNCE dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for CNCE dated on 2019-10-12: Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV 2019

Financial news for CNCE dated on 2019-10-06: The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck

Financial news for CNCE dated on 2019-10-03: H.C. Wainwright Reiterates Buy on Concert Pharmaceuticals, Lowers Price Target to \$25

Financial news for CNCE dated on 2019-10-02: The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data

Financial news for CNCE dated on 2019-10-02: Concert Pharmaceuticals to Provide Overview of Clinical Pipeline at Cantor Healthcare Conference Oct. 3

Financial news for CNCE dated on 2019-10-01: Stocks That Hit 52-Week Lows On Tuesday

Financial news for CNCE dated on 2019-10-01: The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines

Financial news for CNCE dated on 2019-09-30: SunTrust Robinson Humphrey Maintains Buy on Concert Pharmaceuticals, Lowers Price Target to \$20

Financial news for CNCE dated on 2019-09-30: Mizuho Maintains Buy on Concert Pharmaceuticals, Lowers Price Target to \$18

Financial news for CNCE dated on 2019-09-30: Hearing Mizuho Has Cut its Price Target on Concert Pharma

Financial news for CNCE dated on 2019-09-30: 52 Biggest Movers From Friday

Financial news for CNCE dated on 2019-09-27: 34 Stocks Moving In Friday's Mid-Day Session

Financial news for CNCE dated on 2019-09-17: Concert Pharma Reports Completion Of Enrollment In Second Open Label Trial Of CTP-543 To Evaluate Once-Daily vs Twice-Daily Dosing In Patients With Alopecia Areata

Financial news for CNCE dated on 2019-09-12: Concert Pharma Highlights CTP-543 Phase 2 Alopecia Areata Data Selected For Late-Breaker Oral Presentation At EADV Congress Oct. 12, 2019

Financial news for CNCE dated on 2019-09-10: The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris

Financial news for CNCE dated on 2019-09-08: The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight

Financial news for CNCE dated on 2019-09-05: 60 Biggest Movers From Yesterday

Financial news for CNCE dated on 2019-09-04: 46 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CNCE dated on 2019-09-04: UPDATE: Mizuho On Concert Pharmaceuticals Believes 'the latest data compares favorably to competitors' data and we see potential for CTP-543 to be best-in-class for the treatment of AA'

Financial news for CNCE dated on 2019-09-04: UPDATE: Mizuho Reiterates Buy On Concert Pharmaceuticals, Raises Target To \$29 As Firm Notes Co's 'Strong Data from CTP-543 12mg Dose'; Firm Raises 'probability of success for CTP-543 from 35% to 60%'

Financial news for CNCE dated on 2019-09-04: Mizuho Maintains Buy on Concert Pharmaceuticals, Raises Price Target to \$29

Financial news for CNCE dated on 2019-09-04: 66 Biggest Movers From Yesterday

Financial news for CNCE dated on 2019-09-03: Concert Pharmaceuticals shares are trading higher after the company's Phase 2 trial of CTP-543 in Alopecia Areata patients met its primary endpoint in both the 8 mg and 12 mg cohorts.

Financial news for CNCE dated on 2019-09-03: Concert Pharmaceuticals Reports CTP-543 Achieved Primary Endpoint In 8 mg And 12 mg Twice-Daily Dosing Cohorts

Financial news for CNCE dated on 2019-08-01: Concert Pharmaceuticals Q2 EPS \$(0.78)

Beats \$(0.89) Estimate

Financial news for CNCE dated on 2019-08-01: The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Financial news for CNCE dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for CNCE dated on 2019-06-25: 60 Biggest Movers From Yesterday

Financial news for CNCE dated on 2019-06-24: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for CNCE dated on 2019-06-24: Benzinga's Top Upgrades, Downgrades For June 24, 2019

Financial news for CNCE dated on 2019-06-24: Concert Pharmaceuticals shares are trading higher after SunTrust Robinson Humphrey initiated coverage on the stock with a Buy rating and a price target of \$30 per share.

Financial news for CNCE dated on 2019-06-24: SunTrust Robinson Humphrey Initiates Coverage On Concert Pharmaceuticals with Buy Rating, Announces \$30 Price Target

Financial news for CNCE dated on 2019-06-13: UPDATE: Janney Upgrades Concert Pharma To Buy 'on clinical progress with CTP-692, a program we believe has blockbuster potential that adds a Ph.2-ready program to a portfolio that includes Ph.2 CTP-543 and partnered program, Ph.3 AVP-786 (data 2H19)'

Financial news for CNCE dated on 2019-06-13: Benzinga's Top Upgrades, Downgrades For June 13, 2019

Financial news for CNCE dated on 2019-06-13: Janney Capital Upgrades Concert Pharmaceuticals to Buy

Financial news for CNCE dated on 2019-06-12: Concert Pharmaceuticals Reports Results From Phase 1 Studies Evaluating CTP-692 In Healthy Volunteers; Co. Expects To Initiate Phase 2 Trial In Patients With Schizophrenia In Q4

Financial news for CNCE dated on 2019-06-11: 52 Biggest Movers From Yesterday

Financial news for CNCE dated on 2019-06-05: Concert Pharmaceuticals Completes Enrollment In Open Label Trial To Evaluate Once-Daily vs. Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata

Financial news for CNCE dated on 2019-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for CNCE dated on 2019-05-16: Concert Pharma Reports Initiation Of New Open Label Trial To Evaluate Once-Daily vs Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata

Financial news for CNCE dated on 2019-05-02: The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

Financial news for CNCE dated on 2019-05-02: Concert Pharmaceuticals Q1 EPS \$(0.93) Misses \$(0.62) Estimate, Sales \$1.005M Miss \$5.35M Estimate

Financial news for CNCE dated on 2019-04-25: The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

Financial news for CNCE dated on 2019-04-21: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for CNCE dated on 2019-04-12: The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug

Financial news for CNCE dated on 2019-04-11: Shares of several healthcare companies are trading lower. Not seeing any immediate news to explain price action.

Financial news for CNCE dated on 2019-04-10: Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial Of CTP-692 As Adjunctive Treatment For Schizophrenia

Financial news for CNCE dated on 2019-04-09: Stifel Nicolaus Maintains Buy on Concert Pharmaceuticals, Lowers Price Target to \$18

Financial news for CNCE dated on 2019-04-09: 50 Biggest Movers From Yesterday

Financial news for CNCE dated on 2019-04-08: Concert Pharmaceuticals Comments On Decision From Patent Trial and Appeal Board In IPR Proceeding; Says Decision Does Not

Affect Other Programs In Portfolio

Financial news for CNCE dated on 2019-04-08: Concert Pharmaceuticals shares are trading lower after the company lost an IPR patent. The PTAB ruled that Incyte proved Concert's '149 patent claims were unpatentable.

Financial news for CNCE dated on 2019-04-08: Concert Pharmaceuticals Shares Resume Trade, Down 20.8%

Financial news for CNCE dated on 2019-04-08: Concert Pharmaceuticals Shares Halted On Circuit Breaker

Financial news for CNCE dated on 2019-04-08: Concert Pharmaceuticals Loses IPR Patent Trial As PTAB Rules Incyte Proved That Concert '149 Patent Claims Are Unpatentable

Financial news for CNCE dated on 2019-04-03: 54 Biggest Movers From Yesterday

Financial news for CNCE dated on 2019-03-25: 60 Biggest Movers From Friday

Financial news for CNCE dated on 2019-03-12: Concert Pharmaceuticals To Present At Oppenheimer Healthcare Conference

Financial news for CNCE dated on 2019-03-06: Concert Pharmaceuticals Announces Initiation Of Open Label Trial To Evaluate Once-Daily vs Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata

Financial news for CNCE dated on 2019-03-01: Concert Pharma Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Academy of Dermatology Annual Meeting: Showed Statistically Significant Effect on Primary Endpoint

Financial news for CNCE dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for CNCE dated on 2019-02-28: Concert Pharmaceuticals Q4 EPS \$(0.89) Misses \$(0.74) Estimate, Sales \$13K Up From \$12K YoY

Financial news for CNCE dated on 2019-02-11: Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting

Financial news for CNCE dated on 2019-01-24: Concert Pharma Initiate Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia

Financial news for CNCE dated on 2019-01-22: Concert Pharmaceuticals Completes Enrollment Of 12 Mg Cohort In Phase 2a Trial Of Ctp-543 In Alopecia Areata

Financial news for CNCE dated on 2018-12-18: UPDATE: Mizuho On Concert Pharma Notes Early Competitor Data From Aclaris Therapeutics' Topical JAK 1/3 Treatment Of Alopecia Areata Failed To Impress

Financial news for CNCE dated on 2018-12-18: Mizuho Reiterates Buy, \$26 Target On Concert Pharma, Calls CTP-543 'best-in-class for the treatment of moderate/severe AA'

Financial news for CNCE dated on 2018-12-17: Concert Pharmaceuticals Initiates Phase 1 Clinical Program of CTP-692 for the Treatment of Schizophrenia

Financial news for CNCE dated on 2018-11-19: 55 Biggest Movers From Friday

Financial news for CNCE dated on 2018-11-16: 48 Stocks Moving In Friday's Mid-Day Session

Financial news for CNCE dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for CNCE dated on 2018-11-14: The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut

Financial news for CNCE dated on 2018-11-13: 70 Biggest Movers From Yesterday

Financial news for CNCE dated on 2018-11-12: Concert Pharma's CTP-543 Achieved its Primary Endpoint in the 8 mg Twice-Daily Cohort

Financial news for CNCE dated on 2018-11-06: 52 Biggest Movers From Yesterday

Financial news for CNCE dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for CNCE dated on 2018-11-01: Concert Pharma Q3 EPS \$(0.74) Down From \$5.44 YoY, Sales \$11K Down From \$143.844M YoY

Financial news for CNCE dated on 2018-09-26: UPDATE: Concert Pharma Amendment Provides For Added Patients To Be Enrolled To Evaluate 12 mg Dose Of CTP-543 Or Placebo Twice Daily For 24 Weeks

Financial news for CNCE dated on 2018-09-26: Concert Pharma Reports Amendment Protocol Of Phase 2a Trial To Evaluate 12 mg Twice-Daily Dose Cohort CTP-453 For Treatment Of Alopecia Areata

Financial news for CNCE dated on 2018-09-18: Stocks Which Set New 52-Week Low Yesterday, September 17th

Financial news for CNCE dated on 2018-09-17: Stocks Which Set New 52-Week Low Friday, September 14

Financial news for CNCE dated on 2018-09-14: Stocks Which Set New 52-Week Low Yesterday, September 13th

Financial news for CNCE dated on 2018-09-14: The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut

Financial news for CNCE dated on 2018-09-13: Janney Capital Initiates Coverage On Concert Pharmaceuticals with Neutral Rating

Financial news for CNCE dated on 2018-09-12: Stocks Which Set New 52-Week Low Yesterday, September 11th

Financial news for CNCE dated on 2018-08-02: Concert Pharmaceuticals Q2 EPS \$(0.57) Beats \$(0.62) Estimate, Sales \$2K Miss \$10K Estimate

Financial news for CNCE dated on 2018-05-03: Concert Pharmaceuticals Q1 EPS \$(0.19) Beats \$(0.58) Estimate

Financial news for CNCE dated on 2018-04-25: Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata

Financial news for CNCE dated on 2018-04-06: 34 Biggest Movers From Yesterday

Financial news for CNCE dated on 2018-04-03: 41 Biggest Movers From Yesterday

Financial news for CNCE dated on 2018-03-12: 44 Biggest Movers From Friday

Financial news for CNCE dated on 2018-03-09: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for CNCE dated on 2018-03-09: Benzinga's Top Upgrades, Downgrades For March 9, 2018

Financial news for CNCE dated on 2018-03-09: Mizuho Upgrades Concert Pharmaceuticals to Buy from Neutral; Raises PT to \$27 from \$23

Financial news for CNCE dated on 2018-03-02: 45 Biggest Movers From Yesterday

Financial news for CNCE dated on 2018-03-01: 34 Stocks Moving In Thursday's Mid-Day Session

Financial news for CNCE dated on 2018-03-01: Concert Pharmaceuticals Reports Q4 EPS \$(0.26) vs \$(0.43) Est.

Financial news for CNCE dated on 2018-02-12: Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata

Financial news for CNCE dated on 2018-01-16: 38 Biggest Movers From Friday

Financial news for CNCE dated on 2018-01-12: Mid-Afternoon Market Update: Tuniu Gains After Announcing \$100M Share Repurchase Program; Aradigm Shares Slide

Financial news for CNCE dated on 2018-01-12: Concert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades

Financial news for CNCE dated on 2018-01-12: Concert Pharma Shares Down 26.56% Despite Earlier FDA Grant Of Fast Track Designation For CTP-543; Mizuho Downgraded Shares To Neutral Citing Patent Board Decision Not To Grant Company A Post Grant Review In Litigation With Incyte Over CTP-543

Financial news for CNCE dated on 2018-01-12: 33 Stocks Moving In Friday's Mid-Day

Session

Financial news for CNCE dated on 2018-01-12: Mid-Day Market Update: Dow Surges Over 200 Points; AquaBounty Technologies Shares Plummet

Financial news for CNCE dated on 2018-01-12: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for CNCE dated on 2018-01-12: Concert Pharma Granted Fast Track Designation for CTP-543 for the Treatment of Alopecia Areata

Financial news for CNCE dated on 2017-12-19: UPDATE: Concert Pharmaceuticals Shares Up 8.42%; Earlier UBS Raised Price Target From \$22 to \$34 Citing Strength Of Clinical Candidates And Underestimated Probability Of Success For CTP-543 Treatment

Financial news for CNCE dated on 2017-12-19: Concert Pharmaceuticals Shares Up 8.71%; Hearing UBS Raised Price Target To \$34 Today, As Yet Unconfirmed

Financial news for CNCE dated on 2017-12-18: Concert Pharmaceuticals Names Marc Becker CFO

Financial news for CNCE dated on 2017-12-13: Concert Pharma Announces it Will Be Added to NASDAQ Biotechnology Index

Financial news for CNCE dated on 2017-11-09: Concert Pharmaceuticals Reports Q3 EPS \$5.61 vs \$(0.51) In Prior Year Period, Sales \$143.84M

Financial news for CNCE dated on 2017-10-26: Benzinga's Top Upgrades, Downgrades For October 26, 2017

Financial news for CNCE dated on 2017-10-26: Mizuho Initiates Coverage On Concert Pharmaceuticals with Buy Rating, Announces \$23.00 Price Target

Financial news for CNCE dated on 2017-10-24: Concert Pharmaceuticals Shares Up 11.49% On High Volume; Late Monday BVF Partners Disclosed Purchase Of 331.916K Shares At \$15.8375 In Form 4

Financial news for CNCE dated on 2017-10-20: 38 Biggest Movers From Yesterday

Financial news for CNCE dated on 2017-10-19: Concert Pharma Reports PTAB Has Denied Incyte Petition Challenging CTP-543 Patent

Financial news for CNCE dated on 2017-09-07: Wells Fargo Healthcare Conference Concludes Today, Presenters Include: Foundation Medicine, Tenet Healthcare, bluebird bio, Envision Healthcare, Ironwood Pharmaceuticals, Quorum Health, and Concert Pharmaceuticals

Financial news for CNCE dated on 2017-07-24: 18 Biggest Mid-Day Gainers For Monday

Financial news for CNCE dated on 2017-07-24: Concert Pharma Shares Rally Over \$15 Level Following New Buy Rating, \$20 Price Target

Financial news for CNCE dated on 2017-07-24: Benzinga's Top Upgrades, Downgrades For July 24, 2017

Financial news for CNCE dated on 2017-07-24: H.C. Wainwright Initiates Coverage On Concert Pharmaceuticals with Buy Rating, Announces \$20.00 Price Target

Financial news for CNCE dated on 2017-07-24: Concert Pharma Announces Termination of the HSR Act Waiting Period for CTP-656 Asset Purchase Agreement with Vertex

Financial news for CNCE dated on 2017-07-10: Concert Pharma Gets Clinical Hold on CTP-543 Lifted

Financial news for CNCE dated on 2017-06-12: Concert Pharma Receives \$30M of Venture Debt Financing from Hercules Capital

Financial news for CNCE dated on 2017-05-30: Concert Pharma CFO to Step Down and Return to Investment Banking

Financial news for CNCE dated on 2017-05-24: Concert Pharma Reports Shareholder Approval of CTP-656 Asset Purchase Deal with Vertex

Financial news for CNCE dated on 2017-05-22: Concert Pharmaceuticals Receives Second Request from FTC for the Acquisition of CTP-656 from Vertex Pharma

Financial news for CNCE dated on 2017-05-17: UPDATE: Concert Says FDA Requested Review of Recently Completed Non-Clinical Studies, Did Not Cite a Safety Concern

Financial news for CNCE dated on 2017-05-17: Concert Pharma Reports Clinical Hold on Phase 2a Trial for CTP-543

Financial news for CNCE dated on 2017-05-17: Concert Pharma Shares Halted News Pending

Financial news for CNCE dated on 2017-05-02: Concert Pharmaceuticals Reports Q1 EPS \$(0.60) vs \$(0.63) In Prior Year Period

Financial news for CNCE dated on 2017-04-05: UPDATE: Concert Pharma Cites 'a late emerging clinical tablet appearance issue' for CTP-543 Delay; Sees Initiating, Enrolling Trial in '17, Topline Data in Q1'18

Financial news for CNCE dated on 2017-04-05: 8-K from Concert Pharma Shows News of Unexpected Delay in Initiation of CTP-543 Phase 2a Trial for Alopecia Areata

Financial news for CNCE dated on 2017-03-07: Wall Street's M&A Chatter From March 6

Financial news for CNCE dated on 2017-03-06: Mid-Afternoon Market Update: GoPro Slides Following Goldman Sachs Downgrade; TG Therapeutics Shares Spike Higher

Financial news for CNCE dated on 2017-03-06: 15 Biggest Mid-Day Gainers For Monday

Financial news for CNCE dated on 2017-03-06: Mid-Day Market Update: Dow Falls 80 Points; Concert Pharma Shares Spike Higher

Financial news for CNCE dated on 2017-03-06: Mid-Morning Market Update: Markets Open Lower; Deutsche Bank Plans to Raise Capital

Financial news for CNCE dated on 2017-03-06: Q4 2016 Real-Time Call Brief

Financial news for CNCE dated on 2017-03-06: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for CNCE dated on 2017-03-06: Concert Pharma Shares Resume Trade, Now Up 14%

Financial news for CNCE dated on 2017-03-06: A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Factory Orders Data

Financial news for CNCE dated on 2017-03-06: Concert Pharma Shares to Resume Trade at 7:45 a.m. EST

Financial news for CNCE dated on 2017-03-06: Concert Pharmaceuticals Reports Q4 EPS \$(0.54) vs. \$(0.61) Est., Sales \$21K

Financial news for CNCE dated on 2017-03-06: Vertex to Acquire CTP-656 from Concert Pharmaceuticals For \$160M Cash And Potential \$90M In Milestones

Financial news for CNCE dated on 2017-03-06: TG Therapeutics and Concert Pharma Halted

Financial news for CNCE dated on 2017-03-05: Concert Pharmaceuticals Presents Favorable CTP-543 Phase 1 Results at American Academy of Dermatology Annual Meeting

Financial news for CNCE dated on 2017-01-20: Concert Pharma Reports Received FDA Orphan Drug Designation for CTP-656 for Treatment of Cystic Fibrosis

Financial news for CNCE dated on 2017-01-17: 12 Biggest Mid-Day Losers For Tuesday

Financial news for CNCE dated on 2017-01-17: Concert Pharmaceuticals Provides Details on CTP-656 Development in U.S. and Europe

Financial news for CNCE dated on 2016-12-21: Concert Pharmaceuticals Begins Phase 2 Clinical Trial Evaluating CTP-656 for the Treatment of Cystic Fibrosis

Financial news for CNCE dated on 2016-12-14: Concert Pharmaceuticals Announces CTP-543 Positive Top-Line Phase 1 Results, CTP-543 to Advance into Phase 2 in First Quarter of 2017

Financial news for CNCE dated on 2016-11-08: Concert Pharma Reports Q3 EPS \$(0.51) vs \$(0.63) Est., Sales \$26K vs \$420K Est.

Financial news for CNCE dated on 2016-09-30: 7 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for CNCE dated on 2016-09-22: 25 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for CNCE dated on 2016-08-09: Concert Pharma Reports Q2 EPS \$(0.60) vs \$(0.63) Est., Sales \$71K vs \$30K Est.

Financial news for CNCE dated on 2016-07-01: Stifel Nicolaus Initiates Coverage on Concert Pharmaceuticals at Buy

Financial news for CNCE dated on 2016-06-20: Concert Pharmaceuticals IR Tells Benzinga There is No News from the Co

Financial news for CNCE dated on 2016-06-20: Concert Pharma Shares Resume Trade, Touch Fresh Session Low at \$10.20, Now Up ~\$0.50 from Low Tick

Financial news for CNCE dated on 2016-06-20: Concert Pharma Shares Plunge Into Negative Territory; Halted on Circuit Breaker Down ~7.5%

Financial news for CNCE dated on 2016-06-10: Concert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference , Concert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference

Financial news for CNCE dated on 2016-05-19: Concert Pharma Reports Initiation of Phase 1 Trial of CTP-543 as New Treatment for Alopecia Areata

Financial news for CNCE dated on 2016-05-05: Concert Pharmaceuticals Reports Q1 EPS \$(0.63) vs. Est. \$(0.45)

Financial news for CNCE dated on 2016-04-28: Concert Pharmaceuticals Reports Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-656 For Cystic Fibrosis Treatment

Financial news for CNCE dated on 2016-03-01: Concert Pharmaceuticals Reports Q4 EPS \$0.03 vs. Est. \$(0.05), Rev. \$10.3M vs. Est. \$11.24M

Financial news for CNCE dated on 2016-02-29: Concert Pharma Says CTP-656 Phase 1 Results Superior to Kalydeco

Financial news for CNCE dated on 2015-11-12: Concert Pharmaceuticals Initiates Phase 1 Multiple Ascending Dose Trial with CTP-656 for Cystic Fibrosis

Financial news for CNCE dated on 2015-11-05: Concert Pharmaceuticals Reports Q3 EPS \$(0.39) vs. Est. \$(0.31), Rev. \$1.709M vs. Est. \$4.5M

Financial news for CNCE dated on 2015-10-08: Concert Pharmaceuticals Highlights CTP-656 Phase 1 Results at North American Cystic Fibrosis Conference

Financial news for CNCE dated on 2015-10-08: Concert Pharmaceuticals Announces \$8 Million Milestone from Celgene

Financial news for CNCE dated on 2015-09-22: Concert Pharmaceuticals Volatile Following Report of Results of a Phase 1 Trial of CTP-656

Financial news for CNCE dated on 2015-09-22: Concert Pharmaceuticals Reports Results of a Phase 1 Trial That Shows CTP-656 Achieved a Superior Pharmacokinetic Profile to Kalydeco

Financial news for CNCE dated on 2015-08-12: Benzinga's Top Initiations

Financial news for CNCE dated on 2015-08-12: Brean Capital Initiates Coverage on Concert Pharmaceuticals at Buy, Announces \$21.00 PT

Financial news for CNCE dated on 2015-08-05: Concert Pharmaceuticals Reports Q2 EPS \$1.80 vs. Est. \$(0.46) May Not Compare, Rev. \$53.409M

Financial news for CNCE dated on 2015-06-08: Concert Pharmaceuticals Receives \$50M Payment from Auspex Pharmaceuticals

Financial news for CNCE dated on 2015-05-05: Flagship Ventures Forms Strategic Innovation Partnerships with AstraZeneca, Nestle Health Science and Bayer CropScience

Financial news for CNCE dated on 2015-03-30: Zachary Prensky @Zackfoot Tweet: \$CNCE now my biggest position, bout LT and a trading block

Financial news for CNCE dated on 2015-03-19: Morning Market Losers

Financial news for CNCE dated on 2015-03-19: Concert Pharmaceuticals Announces Pricing of Public Offering, 3.3M Shares At \$15.15/Share

Financial news for CNCE dated on 2015-03-19: Benzinga's Top #PreMarket Losers

Financial news for CNCE dated on 2015-03-12: Concert Pharma Begins Phase 1 Deuterated

Ivacaftor Evaluation For Cystic Fibrosis

Financial news for CNCE dated on 2015-02-04: Concert Pharmaceuticals Names James V. Cassella as Chief Development Officer

Financial news for CNCE dated on 2014-12-09: Jazz Pharma, Concert Pharma Report JZP-386 Program Update

Financial news for CNCE dated on 2014-10-13: Concert Pharmaceuticals Presents Positive Data From Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate For The Treatment of Spasticity

Financial news for CNCE dated on 2014-09-17: US Stock Futures Flat; All Eyes On FOMC Decision

Financial news for CNCE dated on 2014-09-17: Concert Pharmaceuticals Initiates CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration

Financial news for CNCE dated on 2014-08-12: Concert Pharma Reports Q2 EPS of \$(0.45) vs \$(0.42) Est; Revenue of \$1.24M vs \$1.30M Est

Financial news for CNCE dated on 2014-07-16: Concert Pharma Announces Completed Steps To Lift Clinical Hold

Financial news for CNCE dated on 2014-07-08: Concert Pharma Announces Successful End of Phase 2

Financial news for CNCE dated on 2014-06-26: Ladenburg Thalmann Initiates Coverage on Concert Pharma at Buy, Announces \$24.00 PT

Financial news for CNCE dated on 2014-05-23: Morning Market Movers Friday, May 23, 2014

Financial news for CNCE dated on 2014-05-14: Concert Pharma Reports Q1 EPS of \$(0.76) vs \$(0.49) Est

Financial news for CNCE dated on 2014-04-25: UPDATE: Concert Pharamceuticals Says Primary Endpoint of the Trial was Change after 24 Weeks in UACR, Trial did Not Meet this Endpoint, at 48 Weeks

Financial news for CNCE dated on 2014-04-25: Concert Pharmaceuticals Presents Positive 48-Week Results from Phase 2 Clinical Trial of CTP-499

Financial news for CNCE dated on 2014-03-19: Roth Capital Initiates Coverage on Concert Pharma at Buy, Announces \$28.00 PT

Financial news for CNCE dated on 2014-03-10: Perion Network, Horizon Pharma, Manitex, Attunity, Galena Biopharma, Concert Pharmaceuticals, Spansion, Magellan Petroleum, JAKKS Pacific Presenting at Roth Conference at 12:00 PM ET

Financial news for CNCE dated on 2014-03-10: Benzinga's Top Initiations

Financial news for CNCE dated on 2014-03-10: UBS Initiates Coverage on Concert Pharma at Buy, Announces \$25.00 PT

Financial news for CNCE dated on 2014-03-10: Wells Fargo Initiates Coverage on Concert Pharma at Outperform

Financial news for CNCE dated on 2014-03-10: JMP Initiates Coverage on Concert Pharma at Market Outperform, Announces \$28.00 PT

Financial news for CNCE dated on 2014-03-10: UBS Initiates Coverage on Concert Pharma at Buy, Announces \$25.00 PT

Financial news for CNCE dated on 2014-02-13: Shares of Concert Pharma Open for Trade at \$15.75 After Pricing at \$14/Share

Financial news for CNCE dated on 2014-02-13: Waiting on IPOs for Amedica (AMDA), Concert Pharma (CNCE)

Financial news for CNCE dated on 2014-01-13: Concert Pharma Files \$74.8M IPO, Will List on NASDAQ Under 'CNCE'